KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Assets (2016 - 2026)

TherapeuticsMD filings provide 17 years of Non-Current Assets readings, the most recent being $22.3 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 13.24% to $22.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $94.7 million, a 12.27% decrease, with the full-year FY2025 number at $23.2 million, down 12.62% from a year prior.
  • Non-Current Assets hit $22.3 million in Q1 2026 for TherapeuticsMD, down from $23.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $49.0 million in Q1 2022 to a low of $22.3 million in Q1 2026.
  • Median Non-Current Assets over the past 5 years was $30.6 million (2024), compared with a mean of $32.1 million.
  • The widest YoY moves for Non-Current Assets: up 6.33% in 2022, down 29.79% in 2022.
  • TherapeuticsMD's Non-Current Assets stood at $35.1 million in 2022, then dropped by 10.24% to $31.5 million in 2023, then decreased by 15.71% to $26.6 million in 2024, then fell by 12.62% to $23.2 million in 2025, then decreased by 3.85% to $22.3 million in 2026.
  • The last three reported values for Non-Current Assets were $22.3 million (Q1 2026), $23.2 million (Q4 2025), and $24.2 million (Q3 2025) per Business Quant data.